Premium
Prophylactic augmentin in prelabor preterm rupture of the membranes
Author(s) -
Magwali T.L.,
Chipato T.,
Majoko F.,
Rusakaniko S.,
Mujaji C.
Publication year - 1999
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/s0020-7292(99)00036-3
Subject(s) - medicine , gestation , neonatal sepsis , prophylactic treatment , gestational age , obstetrics , sepsis , group b , antibiotics , statistical significance , randomized controlled trial , rupture of membranes , antibiotic prophylaxis , pregnancy , surgery , genetics , microbiology and biotechnology , biology
Objective: To determine whether the use of prophylactic Augmentin in PPROM prolongs gestation and reduces neonatal and maternal morbidity due to sepsis. Method: Study setting was Harare Maternity Hospital, Zimbabwe. Women with PPROM between 26 and 36 weeks' gestation were randomly allocated either to a group given a course of prophylactic oral Augmentin or another receiving no prophylactic antibiotic treatment. The calculated sample size was 72 women per group. Data were analyzed using the EPI INFO program. Results: A total of 171 women were recruited into the study, 84 in the Augmentin group and 87 in the No Treatment group. The group receiving prophylactic Augmentin had a significantly longer latency period between rupture of membranes and delivery. There was a trend towards increased neonatal and maternal morbidity due to sepsis in the No Treatment group although no statistical significance was reached. Conclusion: The use of prophylactic Augmentin in PPROM significantly prolongs gestation. It appears to decrease neonatal and maternal morbidity due to sepsis.